Growth hormone treatment and pseudotumor cerebri: Coincidence or close relationship?

Journal of Pediatric Endocrinology and Metabolism

Volumn 15, Issue SUPPL. 2, 2002, Pages 723-730

  Reeves, Grafton D ^a   Doyle, Daniel A ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Growth hormone; Idiopathic intracranial hypertension; Papilledema; Pseudotumor cerebri

Indexed keywords

ACETAZOLAMIDE; GLUCOCORTICOID; RECOMBINANT GROWTH HORMONE; GROWTH HORMONE;

ADOLESCENT; AFFECTIVE NEUROSIS; ARTICLE; BENIGN TUMOR; BLINDNESS; BRAIN PSEUDOTUMOR; CHILD; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; LUMBAR PUNCTURE; MALE; NAUSEA AND VOMITING; NERVE DECOMPRESSION; PAPILLEDEMA; POSTMARKETING SURVEILLANCE; PROBABILITY; RISK FACTOR; SHUNTING; TREATMENT OUTCOME; AGE; BODY MASS; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FACTUAL DATABASE; OBESITY; PRESCHOOL CHILD; UNITED STATES;

ADOLESCENT; AGE FACTORS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE; HUMANS; MALE; OBESITY; PSEUDOTUMOR CEREBRI; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0036287409     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2002.15.s2.723     Document Type: Article

References (24)

1. The incidence of pseudotumor cerebri: Population studies in Iowa and Louisiana
2. Pediatric pseudotumor cerebri: Descriptive epidemiology
3. Pseudotumor cerebri following treatment with growth hormone
4. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension
5. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone
6. Benign intracranial hypertension induced by growth hormone treatment
7. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience
8. A risk-benefit assessment of growth hormone use in children
9. Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
10. Pseudotumor cerebri in children receiving recombinant human growth hormone
11. Safety issues in children and adolescents during growth hormone therapy: A review
12. Adverse events during GH treatment: 10 years' experience in KIGS, a pharmacoepidemiological survey
13. Growth hormone safety update from the National Cooperative Growth Study
14. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters
15. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
16. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system
17. Effects of growth hormone on the metabolism of lipids and water and their potential in causing adverse events during growth hormone treatment
18. Pseudotumor cerebri
19. Idiopathic intracranial hypertension: Relation of age and obesity in children
20. Magnetic resonance imaging in pseudotumor cerebri
21. MR imaging of pituitary morphology in idiopathic intracranial hypertension
22. MR imaging of idiopathic intracranial hypertension
23. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension)